AU2013402794B2 - Cancer treatment with combination of plinabulin and taxane - Google Patents

Cancer treatment with combination of plinabulin and taxane Download PDF

Info

Publication number
AU2013402794B2
AU2013402794B2 AU2013402794A AU2013402794A AU2013402794B2 AU 2013402794 B2 AU2013402794 B2 AU 2013402794B2 AU 2013402794 A AU2013402794 A AU 2013402794A AU 2013402794 A AU2013402794 A AU 2013402794A AU 2013402794 B2 AU2013402794 B2 AU 2013402794B2
Authority
AU
Australia
Prior art keywords
docetaxel
plinabulin
npi
tumor
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013402794A
Other languages
English (en)
Other versions
AU2013402794A1 (en
Inventor
Lan Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeyondSpring Inc
Original Assignee
BeyondSpring Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52812462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013402794(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BeyondSpring Inc filed Critical BeyondSpring Inc
Publication of AU2013402794A1 publication Critical patent/AU2013402794A1/en
Assigned to BEYONDSPRING INC. reassignment BEYONDSPRING INC. Request for Assignment Assignors: BEYONDSPRING PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2013402794B2 publication Critical patent/AU2013402794B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013402794A 2013-10-11 2013-10-11 Cancer treatment with combination of plinabulin and taxane Active AU2013402794B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/085075 WO2015051543A1 (en) 2013-10-11 2013-10-11 Cancer treatment with combination of plinabulin and taxane

Publications (2)

Publication Number Publication Date
AU2013402794A1 AU2013402794A1 (en) 2016-05-12
AU2013402794B2 true AU2013402794B2 (en) 2020-02-27

Family

ID=52812462

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013402794A Active AU2013402794B2 (en) 2013-10-11 2013-10-11 Cancer treatment with combination of plinabulin and taxane

Country Status (18)

Country Link
US (2) US10596169B2 (OSRAM)
EP (1) EP3076972B1 (OSRAM)
JP (1) JP6411523B2 (OSRAM)
KR (1) KR102225371B1 (OSRAM)
CN (1) CN105705148B (OSRAM)
AU (1) AU2013402794B2 (OSRAM)
BR (1) BR112016007946A2 (OSRAM)
CA (1) CA2926771C (OSRAM)
DK (1) DK3076972T3 (OSRAM)
ES (1) ES2902665T3 (OSRAM)
IL (1) IL244984B (OSRAM)
MX (1) MX384751B (OSRAM)
MY (1) MY185650A (OSRAM)
NZ (1) NZ719049A (OSRAM)
RU (1) RU2662298C2 (OSRAM)
SG (1) SG11201602637QA (OSRAM)
WO (1) WO2015051543A1 (OSRAM)
ZA (1) ZA201602380B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170117113A (ko) * 2015-02-12 2017-10-20 비욘드스프링 파마수티컬스, 인코포레이티드. 면역 관문 저해제와 조합한 플리나불린의 용도
RU2728796C2 (ru) 2015-03-06 2020-07-31 Бейондспринг Фармасьютикалс, Инк. Способ лечения опухоли головного мозга
SG10202008673WA (en) * 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
CN109516981B (zh) * 2015-07-13 2019-10-22 大连万春布林医药有限公司 普那布林组合物
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
KR20240091084A (ko) * 2016-06-06 2024-06-21 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
IL268305B2 (en) * 2017-02-01 2024-08-01 Beyondspring Pharmaceuticals Inc Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced
BR112019018880A2 (pt) * 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals Inc composições de plinabulina e seu uso
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
AU2019216305B2 (en) * 2018-02-01 2024-11-21 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a G-CSF agent
CN108524442B (zh) * 2018-06-05 2022-01-28 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
JP2018199726A (ja) * 2018-09-26 2018-12-20 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
CN113661253B (zh) * 2018-11-14 2024-03-12 大连万春布林医药有限公司 微管蛋白结合剂治疗癌症的方法
CN110507653B (zh) * 2019-08-02 2022-12-02 北京赛而生物药业有限公司 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用
JP2022552011A (ja) * 2019-10-15 2022-12-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 鉄障害を処置するための方法及び組成物
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077940A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
MXPA05001217A (es) 2002-08-02 2005-05-16 Nereus Pharmaceuticals Inc Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
EP2968536B1 (en) 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077940A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Millward, M et al (2012) "Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel" Invest New Drugs 30: 1065–1073 *
Mita, AC et al (2010) "Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC)" Journal of Clinical Oncology 28: 7592-7592 *

Also Published As

Publication number Publication date
IL244984A0 (en) 2016-05-31
EP3076972A1 (en) 2016-10-12
WO2015051543A1 (en) 2015-04-16
ZA201602380B (en) 2022-05-25
MY185650A (en) 2021-05-27
IL244984B (en) 2022-05-01
CA2926771C (en) 2022-07-05
MX2016004441A (es) 2016-10-28
KR20160078987A (ko) 2016-07-05
JP2016536352A (ja) 2016-11-24
DK3076972T3 (da) 2022-01-03
WO2015051543A8 (en) 2016-04-21
SG11201602637QA (en) 2016-05-30
MX384751B (es) 2025-03-14
EP3076972A4 (en) 2017-12-20
NZ719049A (en) 2020-06-26
BR112016007946A2 (pt) 2017-09-12
JP6411523B2 (ja) 2018-10-24
KR102225371B1 (ko) 2021-03-10
CN105705148A (zh) 2016-06-22
US20200281921A1 (en) 2020-09-10
EP3076972B1 (en) 2021-10-06
US10596169B2 (en) 2020-03-24
US20160250209A1 (en) 2016-09-01
CN105705148B (zh) 2021-03-23
RU2016112608A (ru) 2017-11-16
CA2926771A1 (en) 2015-04-16
ES2902665T3 (es) 2022-03-29
AU2013402794A1 (en) 2016-05-12
RU2662298C2 (ru) 2018-07-25

Similar Documents

Publication Publication Date Title
AU2013402794B2 (en) Cancer treatment with combination of plinabulin and taxane
TWI533866B (zh) 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎抗腫瘤用途
JP7113619B2 (ja) リポソーマルイリノテカンによる乳がんの治療
AU2021218871B2 (en) Use of mitoxantrone hydrochloride liposome for treating breast cancer
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
Kollmannsberger et al. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)
JP2013521338A (ja) 小細胞肺癌を治療するための方法
JP2018199726A (ja) プリナブリン及びタキサンの組合せがん治療
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane
CN118873497A (zh) 盐酸米托蒽醌脂质体在治疗乳腺癌中的用途
WO2021185234A1 (zh) 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
TW201705950A (zh) 卡巴他賽及其治療癌症的用途
WO2025209479A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
BR112020011796A2 (pt) uso de tratamento combinado de anticorpo pd-1 e apati-nib para o tratamento de câncer de mama negativo triplo
Fattoruso et al. Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer
WO2025232873A1 (zh) 多西他赛白蛋白组合物治疗胃癌或胃食管结合部癌的用途
HK40082294A (en) Uses of mitoxantrone hydrochloride liposome
WO2024160190A1 (zh) 紫杉醇阳离子脂质体治疗肿瘤的用途
CA3227813A1 (en) Pharmaceutical composition for treating solid tumors
EP4304645A1 (en) Use of oregovomab and bevacizumab, paclitaxel, carboplatin for treatment of brca-wild type platinum sensitive recurrent
WO2025082356A1 (zh) Cldn18_2抗体与化学治疗药物的组合及其应用
Standard et al. Pr PACLITAXEL FOR INJECTION
HK1261494A1 (en) Use of combination of vegfr inhibitor and parp inhibitor in preparation of medicament for treating gastric cancer
US20160143929A1 (en) Administration of glufosfamide for the treatment of cancer
HK1155089A (en) Use of picoplatin and bevacizumab to treat colorectal cancer

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BEYONDSPRING INC.

Free format text: FORMER APPLICANT(S): BEYONDSPRING PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)